"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2. Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus ...

ARPIs provide significant survival benefits in younger mHSPC patients, with a 13% improvement in 5-year overall survival and 21% in progression-free survival. The meta-analysis included data from 11 ...

The MHRA has accepted the marketing authorization application for Anktiva combined with BCG for BCG-unresponsive NMIBC with CIS in the UK. Anktiva received FDA approval in the US in April 2024, and ...

Darolutamide plus ADT significantly improves radiological progression-free survival in mHSPC, reducing progression or death risk by 46%. The treatment effect is more pronounced in low-volume disease, ...

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...